Saba NF, Posner M, Harrington K, Neupane P, et al. Danvatirsen plus pembrolizumab versus pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma (PEMDA-HN): a randomized, phase 2 trial. Clin Cancer Res 2026 Aug 19. doi: 10.1158/1078-0432.CCR-26-0819.
PMID: 42615600